FDA tells GLP-1 makers to warn of potential vision loss side effect
The FDA is requiring all GLP-1 drug makers to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden and permanent vision loss.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
U.S. regulators ordered makers of popular GLP-1 weight-loss drugs to add warnings regarding a potential rare risk of vision loss and eye strokes. Following these directives, coverage of the new FDA warnings quieted without further developments reported in the headlines.
Epilogue added 4d ago, after coverage quieted.
The brief
The U.S. Food and Drug Administration announced Monday that it is requiring new safety warnings on all GLP-1 medications after finding evidence of a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION, an eye condition that can cause sudden vision loss. According to CNBC, the FDA said a causal relationship has not been established, and the condition is rare.
The class-wide labeling action covers a dozen injectable or pill-based drugs used to treat obesity, diabetes and several other medical conditions, including Ozempic, Wegovy, Zepbound and Mounjaro, CBS News reported. NAION is caused by decreased blood flow to the front of the optic nerve, though the underlying cause is not completely understood, the FDA said. Cases have been reported for all currently marketed GLP-1 products.
The FDA decision followed a review of clinical trials, real-world patient data and published studies. CNBC reported that an analysis of 126 trials involving more than 134,000 patients found 6.4 cases of NAION per 100,000 patient-years among GLP-1 users, compared with 3.8 among patients receiving other treatments or placebos. CBS News described the FDA analysis of more than 125 clinical trials as finding roughly 6 cases per 100,000 patients who took a GLP-1 for at least one year, against less than 4 per 100,000 for people taking a placebo or other glucose-lowering medications. The agency also found reports in its electronic reporting system for drug injuries and side effects.
CBS News reported that FDA scientists began looking into the issue after a 2024 medical paper tied the condition to certain patients taking semaglutide, the active ingredient in Ozempic and Wegovy. Dr. Joseph Rizzo, a neuro-ophthalmologist who co-authored that paper, told CBS News he believes the evidence shows GLP-1 usage increases the risk of developing NAION, but he does not discourage patients from taking the medicines, saying, "The medicines have really been profoundly beneficial to a large number of people."
Novo Nordisk, which makes Ozempic and Wegovy, said it "continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines." Eli Lilly, which makes Zepbound and Mounjaro, said in a statement Monday it was "carefully evaluating the update and will respond to FDA promptly." Lilly said the FDA's drug safety communication applies to all medicines with GLP-1 RA activity and does not reference any findings specific to Lilly medicines.
Symptoms include blurred vision, blind spots, distorted colors and other visual disturbances, the FDA said, and patients experiencing such problems should contact a healthcare professional immediately. Rizzo said the vision loss tends to be irreversible and can become progressively worse even if a patient stops taking the medication, and that the two eyes may not be affected to the same degree.
Background in the coverage includes the American Academy of Ophthalmology's estimate that NAION affects between 2 to 10 of every 100,000 adults over age 50 who are not on GLP-1s. CNBC also noted that many GLP-1 drugs carry the FDA's boxed warning over a potential risk of thyroid tumors, with rodent studies showing thyroid C-cell tumors from semaglutide and tirzepatide; it remains unknown whether the drugs cause these tumors in humans. On market reaction, Citi analysts told CNBC the class-wide labeling action is "likely to attract attention but should have limited impact on GLP-1 uptake," given the rarity of NAION and the substantial weight, glycemic, cardiovascular, renal and sleep apnea benefits of the medicines.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 6d ago.
Quick answers
What eye condition is the FDA warning about?
The warning concerns nonarteritic anterior ischemic optic neuropathy, or NAION, a condition caused by decreased blood flow to the front of the optic nerve that can result in sudden decreased vision, including permanent vision loss. The FDA said the underlying cause is not completely understood.
Which drugs are affected by the FDA's new warning?
The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. CBS News said the class includes a dozen injectable or pill-based drugs, including Ozempic, Wegovy, Zepbound and Mounjaro, and that NAION cases have been reported for all currently marketed GLP-1 products.
Has the FDA said GLP-1 drugs cause NAION?
No. CNBC reported that the FDA said a causal relationship has not been established. Novo Nordisk said it "continues to believe the data do not establish a cause-and-effect relationship and we remain confident in the benefit-risk profile of our GLP-1 medicines." Dr. Joseph Rizzo told CBS News he believes the evidence shows GLP-1 usage increases the risk of developing NAION.
How common is NAION and what are the symptoms?
CBS News reported that NAION affects somewhere between 2 to 10 of every 100,000 adults over age 50 who are not on GLP-1s. According to the FDA, symptoms include blurred vision, blind spots, distorted colors and other visual disturbances, and patients experiencing such problems should contact a healthcare professional immediately.
Coverage (9)
- Danger of sudden vision loss: the new FDA warning about GLP-1 weight loss injections Ynetnews · 6d ago
- FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound CNBC · 6d ago
- U.S. Regulators Warn GLP-1 Drugs Carry Possible Rare Blindness Risk WSJ · 6d ago
- FDA orders blindness risk warning on weight loss drugs Sky News · 6d ago
- FDA warns of rare ‘eye stroke’ risk from GLP-1 drugs The Hill · 6d ago
- GLP-1 drugs, popular for weight loss, get FDA warning of rare vision-loss side effect CBS News · 6d ago
- FDA adds rare vision-loss warning to popular GLP-1 drugs News4JAX · 6d ago
- US is requiring weight-loss drug makers to warn about possible loss of eyesight The Independent · 6d ago
- FDA adds rare vision-loss warning to popular GLP-1 drugs AP News · 6d ago
Topics
Related trends
WHO Releases First Guidelines On Type 1 Diabetes In Adults: What To Know
WHO publishes its inaugural clinical guidelines for type 1 diabetes in adults, addressing long-standing care gaps and recommending multiple daily insulin injections.
The GLP-1 boom has a dark side
The FDA orders eye risk warnings on GLP-1 medications like Ozempic and Zepbound, prompting expert guidance.
Taking GLP-1s forever? 5 strategies to keep weight off if you stop
New Cleveland Clinic research maps five evidence-based exit strategies for patients discontinuing GLP-1 weight-loss drugs, a question facing millions as supply and cost pressures mount.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Millions of Americans are altering their GLP-1 drug regimens, skipping doses and stretching supplies due to cost pressures.
Hundreds of children in England prescribed weight-loss jabs, figures show
Recent figures reveal hundreds of children in England are receiving GLP-1 weight-loss prescriptions.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.